CVA Family Office LLC Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

CVA Family Office LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 69.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 560 shares of the medical device company’s stock after buying an additional 230 shares during the period. CVA Family Office LLC’s holdings in DexCom were worth $45,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Centaurus Financial Inc. increased its stake in shares of DexCom by 5.5% during the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock valued at $632,000 after acquiring an additional 64 shares during the last quarter. RMR Wealth Builders grew its position in DexCom by 1.8% in the third quarter. RMR Wealth Builders now owns 5,442 shares of the medical device company’s stock valued at $438,000 after acquiring an additional 98 shares in the last quarter. Ascent Group LLC grew its position in DexCom by 2.1% in the third quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 98 shares in the last quarter. Jaffetilchin Investment Partners LLC boosted its stake in shares of DexCom by 7.7% during the 1st quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock valued at $440,000 after buying an additional 101 shares during the last quarter. Finally, Worth Venture Partners LLC boosted its stake in shares of DexCom by 26.4% during the 1st quarter. Worth Venture Partners LLC now owns 594 shares of the medical device company’s stock valued at $304,000 after buying an additional 124 shares during the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, EVP Barry J. Regan sold 2,010 shares of the stock in a transaction on Monday, March 13th. The stock was sold at an average price of $106.27, for a total value of $213,602.70. Following the completion of the transaction, the executive vice president now owns 70,472 shares in the company, valued at approximately $7,489,059.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Barry J. Regan sold 2,010 shares of the firm’s stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $106.27, for a total transaction of $213,602.70. Following the completion of the sale, the executive vice president now directly owns 70,472 shares in the company, valued at approximately $7,489,059.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 56,844 shares of the firm’s stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $106.15, for a total value of $6,033,990.60. Following the sale, the chief executive officer now owns 369,801 shares of the company’s stock, valued at $39,254,376.15. The disclosure for this sale can be found here. Insiders sold 173,373 shares of company stock worth $18,715,471 in the last quarter. 0.41% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on DXCM. Morgan Stanley raised their price objective on DexCom from $117.00 to $131.00 and gave the stock an “equal weight” rating in a research note on Friday, January 6th. Wolfe Research assumed coverage on DexCom in a report on Thursday, January 26th. They set an “outperform” rating and a $121.00 price target on the stock. Citigroup raised their price target on DexCom from $117.00 to $146.00 and gave the company a “buy” rating in a report on Monday, December 12th. Cowen raised their price target on DexCom from $114.00 to $125.00 and gave the company an “outperform” rating in a report on Friday, February 10th. Finally, Barclays raised their price target on DexCom from $103.00 to $110.00 and gave the company an “equal weight” rating in a report on Monday, February 13th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $123.00.

DexCom Price Performance

NASDAQ:DXCM opened at $114.56 on Friday. The company has a quick ratio of 1.83, a current ratio of 1.99 and a debt-to-equity ratio of 0.56. DexCom, Inc. has a 52-week low of $66.89 and a 52-week high of $134.76. The firm has a market cap of $44.27 billion, a P/E ratio of 141.43, a PEG ratio of 2.69 and a beta of 1.10. The business’s 50-day moving average price is $111.09 and its 200 day moving average price is $106.13.

DexCom (NASDAQ:DXCM – Get Rating) last released its quarterly earnings results on Thursday, February 9th. The medical device company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. DexCom had a return on equity of 16.66% and a net margin of 11.73%. The business had revenue of $815.20 million during the quarter, compared to analyst estimates of $814.52 million. During the same quarter last year, the company posted $0.17 EPS. DexCom’s revenue for the quarter was up 16.8% on a year-over-year basis. As a group, sell-side analysts predict that DexCom, Inc. will post 1.06 earnings per share for the current fiscal year.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.